Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the...

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company...

Nota AI seeks KOSDAQ listing as the first AI optimization tech startup

Nota AI seeks KOSDAQ listing as the first AI optimization tech startup

Strategic partnerships with NVIDIA, Qualcomm, Samsung Electronics accelerate global expansion Revenue grows tenfold in five years, validating tech-driven business model SEOUL, South Korea, May 23, 2025 /PRNewswire/ -- Nota AI, a pioneer in on-device...

Webull Reports First Quarter 2025 Financial Results

Webull Reports First Quarter 2025 Financial Results

Total revenues grew 32% year-over-year to $117 million, reflecting strong account and trading volume growth Customer assets increased 45% year-over-year, driven by increased customer net deposits Disciplined execution alongside robust revenue growth...

China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency

China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency

BEIJING, May 23, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (Nasdaq: CLEU), a China-based company that provides technological consulting services for smart campus solutions and other educational...

Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm

Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm

HANGZHOU, China, May 22, 2025 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the Company's board of directors and the audit committee of the board...

Brighten Up Summertime With Govee New Smart Outdoor Lights

Brighten Up Summertime With Govee New Smart Outdoor Lights

HONG KONG, May 22, 2025 /PRNewswire/ -- Govee, a global leader in smart lighting innovation, today announced the launch of three new additions to the brand's existing vibrant outdoor lighting collection, industry-first dual sensor Outdoor Lamp Post...

Envision Energy Obtained Bureau Veritas Certification for Chifeng Green Ammonia Plant

Envision Energy Obtained Bureau Veritas Certification for Chifeng Green Ammonia Plant

ROTTERDAM, Netherlands, May 22, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced today at the World Hydrogen Summit that its initial phase of Envision's green hydrogen and ammonia project in Chifeng has been...

Workato Named a Leader in the 2025 Gartner® Magic Quadrant™ for iPaaS

Workato Named a Leader in the 2025 Gartner® Magic Quadrant™ for iPaaS

Workato received 4.9/5 ratings in Gartner Peer Insights™ as of 20th May 2025, based on 452 reviews SINGAPORE, May 22, 2025 /PRNewswire/ -- Workato®, the leading Enterprise Orchestration platform, announced today that it has again been recognized as...

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed...

  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...
  • 110
  • menu
    menu